XTL's system offers the potential to biologically validate the effectiveness of drug candidates before embarking on costly human clinical studies. An estimated 4 million individuals are infected with HCV in the United States, and the World Health Organization estimates that 170 million people are infected worldwide. The number of deaths attributable to hepatitis C is expected to triple in the next 10 to 20 years. XTL is a biopharmaceutical company developing fully human monoclonal antibody-based therapeutics with a primary focus on infectious diseases. In addition, XTL has unique, high-value animal models of human diseases including models for testing HBV and HCV therapeutic drugs.
System is available upon request.